MedPath

The Impact of Triptan and Doxycycline on Neuroinflammatory Biomarkers in Acute Migraine

Not Applicable
Withdrawn
Conditions
Migraine Disorders
Headache, Migraine
Migraine
Migraine Headache
Migraine With Aura
Migraine Without Aura
Headache Disorders, Primary
Interventions
Drug: Triptan
Registration Number
NCT01653522
Lead Sponsor
The Cleveland Clinic
Brief Summary

The purpose of this study is to determine the effects of triptans and doxycycline on neuroinflammatory markers in acute migraine.

Detailed Description

Increased inflammatory cytokines and matrix metalloproteinases (MMPs) have been recently implicated in migraine. Inflammation may be a key player in the pathophysiology of migraine by altering blood-brain barrier (BBB) function. As an inflammation induced MMP, MMP-9 is involved in both BBB disruption and neuropathic pain, and is largely derived by neutrophil degranulation during neutrophil-BBB interaction. The tetracycline group of antibiotics may suppress MMP production and neutrophil degranulation. This study aims to investigate known neuroinflammatory biomarkers with a focus on BBB breakdown during acute migraine attacks and assess marker responses to conventional treatment (triptans) and novel MMP targeted therapy (doxycycline). This pilot project data will supplement future projects investigating novel therapeutic strategies such as MMP inhibitors in both migraine acute treatment and prevention.

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Clinical diagnosis of migraine with or without aura that fulfill the 2nd Edition of The International Headache Classification (ICHD-II) criteria
  • Active prescription for an oral triptan medication to abort acute migraines
Exclusion Criteria
  • Tetracycline group or other anti-inflammatory medication use in the preceding three months
  • Pregnant

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
TriptanTriptan-
Triptan + DoxycyclineTriptan-
DoxycyclineDoxycycline-
Triptan + DoxycyclineDoxycycline-
Primary Outcome Measures
NameTimeMethod
Serum neuroinflammatory marker concentrations
Secondary Outcome Measures
NameTimeMethod
Number of participants with adverse events as a measure of safety and tolerability
Time to headache relief
Time to headache recurrence
Headache intensity (four-point scale)

Trial Locations

Locations (1)

Cleveland Clinic

🇺🇸

Cleveland, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath